← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT05283382

Cannabidiol Effects on Learning and Anxiety

◆ AI Clinical Summary

This study examines whether cannabidiol (CBD) can help reduce fear and anxiety responses in college students with social anxiety. Participants will undergo a learning task where they are exposed to anxiety-triggering situations while receiving CBD or a placebo, and researchers will measure how well they can overcome these fears.

Key Objective: The trial tests whether CBD can enhance the brain's natural ability to reduce fear responses and anxiety in people with elevated social anxiety.

Who to Consider: College-age students who experience significant social anxiety and are interested in exploring CBD as a potential treatment for fear and anxiety symptoms should consider enrolling.

Trial Parameters

Condition Anxiety and Fear
Sponsor University of Connecticut
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 160
Sex ALL
Min Age 18 Years
Max Age 50 Years
Start Date 2024-10-30
Completion 2025-12-30
Interventions
Cannabidiol Oral ProductPlacebo

Brief Summary

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.

Eligibility Criteria

Inclusion Criteria: * 18-50 years of age Exclusion Criteria: 1. Difficulties seeing a computer screen 2. Anyone currently taking CBD within the last 24 hours. 3. Anyone using any cannabis product within the last 24 hours. 4. Heart problems or heart disease 5. A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm 6. Are currently pregnant or breast-feeding

Related Trials